SCHEMBL770298

SCHEMBL770298

O=C(NCCCC(=O)N1CCCC2CCCC=C21)Nc1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 16/20 0.46
MEN1 O00255 12/20 0.46
KMT2A Q03164 12/20 0.46
GFER P55789 4/20 0.46
ALDH1A1 P00352 10/20 0.41
HSD17B10 Q99714 9/20 0.41
ALOX15 P16050 7/20 0.41
MAPT P10636 5/20 0.41
HPGD P15428 4/20 0.41
MARS1 P56192 1/20 0.41
PKM P14618 5/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
RAB9A P51151 5/20 0.37
NPC1 O15118 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 3/20 0.36
CYP2C9 P11712 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771768 0.82 CCR3 (0.47) MEN1KMT2AALDH1A1HTTKDM4E
SCHEMBL770828 0.81 MAPT (0.35) GAAALDH1A1MAPTKDM4ERAB9A
SCHEMBL771344 0.80 KEAP1 (0.46) HPGDLMNADPP4CCR3
SCHEMBL769987 0.79 EPHX2 (0.50) GAARAB9ANPC1SMN1; SMN2
SCHEMBL770222 0.79 MEN1 (0.46) MEN1KMT2AALDH1A1RAB9ADPP4
SCHEMBL772557 0.79 EPHX2 (0.50) GAARAB9ANPC1SMN1; SMN2
SCHEMBL772293 0.79 DPP4 (0.56) GAAKMT2AALDH1A1KDM4ERAB9A
SCHEMBL770431 0.78 HTR3A (0.48) KMT2AMAPTSMN1; SMN2TP53LMNA
SCHEMBL771634 0.77 KEAP1 (0.48) HPGDLMNADPP4CCR3
SCHEMBL770000 0.77 POLB (0.44) MEN1KMT2AALDH1A1HSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 GAA 751/4885MEN1 827/4885KMT2A 3868/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 GAA 746/4885MEN1 823/4885KMT2A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.